Actemra gets advisory committee review

09 Jun 2008
News

Executive Summary

Roche's Actemra (tocilizumab) will be evaluated by FDA's Arthritis Drugs Advisory Committee July 29. The rheumatoid arthritis candidate has a September user fee date, and if approved would be the first interleukin-6 receptor inhibitor approved for treatment of moderately to severely active rheumatoid arthritis in adults. Roche is seeking approval as monotherapy and in combination with disease-altering antirheumatic drugs

Existing Subscriber? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS049710

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS049710

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Actemra gets advisory committee review

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Actemra gets advisory committee review

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert